All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How is failure-free survival impacted by belumosudil in cGvHD which has failed prior therapy?
Bookmark this article
During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Aleksandr Lazaryan, MD MPH PhD, Moffitt Cancer Center, Tampa, US. We asked, How is survival impacted by belumosudil in chronic GvHD (cGvHD) which has failed prior therapy?
How is failure-free survival impacted by belumosudil in cGvHD which has failed prior therapy?
In this video, Lazaryan comments on belumosudil, a Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor. He also discusses the phase IIa study KD025-208 (NCT02841995), and the ROCKstar trial (NCT03640481).
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox